UCB Pharma

Lilly, UCB-Backed ViaNautis Scores $25M for Genetic Nanomedicines
Lilly, UCB-Backed ViaNautis Scores $25M for Genetic Nanomedicines
BioSpace
ViaNautis Bio
Eli Lilly
genetic nanomedicine
UCB Pharma
funding
Flag link:
FDA Approves UCB’s Complement Inhibitor for Generalized Myasthenia Gravis
FDA Approves UCB’s Complement Inhibitor for Generalized Myasthenia Gravis
BioSpace
UCB Pharma
Zilbrysq
myasthenia gravis
Flag link:
UCB stakes claim to gMG market as FDA clears Rystiggo
UCB stakes claim to gMG market as FDA clears Rystiggo
Pharmaphorum
UCB Pharma
Rystiggo
myasthenia gravis
FDA
Flag link:
Go or no go? Key FDA decisions for Argenx and Regeneron
Go or no go? Key FDA decisions for Argenx and Regeneron
EP Vantage
FDA
Albireo Pharma
Aldeyra Therapeutics
Alvotech
Amneal Pharmaceuticals
Argenx
ARS Pharmaceuticals
AstraZeneca
Bayer
Bio-Thera Solutions
Biogen
BioMarin Pharmaceutical
Bristol Myers Squibb
Eisai
Eton Pharmaceuticals
F2G
Fabre-Kramer Pharmaceuticals
Fresenius
GSK
Intercept Pharmaceuticals
Ipsen
Ironwood Pharmaceuticals
Merck
Novaliq
Pfizer
Regeneron
Roche
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Takeda
Teva Pharmaceutica
UCB Pharma
Flag link:
UCB partners with Ariceum for treatment of immune-related diseases and cancer
UCB partners with Ariceum for treatment of immune-related diseases and cancer
Biopharma Reporter
UCB Pharma
Ariceum
R&D
radiopharmaceuticals
solid tumors
Flag link:
In upcoming skin disease clash, doctors see Novartis' Cosentyx as an underdog
In upcoming skin disease clash, doctors see Novartis' Cosentyx as an underdog
Fierce Pharma
Novartis
Cosentyx
AbbVie
Humira
hidradenitis suppurativa
UCB Pharma
Flag link:
Spotlight – following Humira in hidradenitis suppurativa
Spotlight – following Humira in hidradenitis suppurativa
EP Vantage
AbbVie
Humira
hidradenitis suppurativa
UCB Pharma
Bimzelx
MoonLake Immunotherapeutics
Flag link:
AAD 2023 – UCB and Acelyrin take aim at hidradenitis suppurativa
AAD 2023 – UCB and Acelyrin take aim at hidradenitis suppurativa
EP Vantage
AAD
hidradenitis suppurativa
AbbVie
Humira
UCB Pharma
Bimzelx
Acelyrin
izokibep
Flag link:
UCB's bimekizumab finally back on the FDA's review list after May rejection
UCB's bimekizumab finally back on the FDA's review list after May rejection
Fierce Pharma
UCB Pharma
psoriasis
bimekizumab
FDA
Flag link:
Praxis ends year on high with $100M biobucks UCB deal for epilepsy medicine
Praxis ends year on high with $100M biobucks UCB deal for epilepsy medicine
Fierce Biotech
Praxis
UCB Pharma
epilepsy
PRAX-020
Flag link:
UCB lowers 2022 profit expectations amid Ukraine war, rising costs
UCB lowers 2022 profit expectations amid Ukraine war, rising costs
Fierce Pharma
UCB Pharma
Ukraine
Russia
generics
Flag link:
UCB’s FDA setback delays competition in U.S. with blockbuster J&J psoriasis drug
UCB’s FDA setback delays competition in U.S. with blockbuster J&J psoriasis drug
MedCity News
UCB Pharma
bimekizumab
psoriasis
FDA
JNJ
Flag link:
UCB takes on Jazz in severe epilepsy with new Fintepla approval
UCB takes on Jazz in severe epilepsy with new Fintepla approval
Pharmaforum
UCB Pharma
FDA
Fintepla
Lennox-Gastaut Syndrome
Jazz Pharma
Epidiolex
Flag link:
AbbVie bets $130M on UCB spinout, bagging early-phase Alzheimer's and depression prospect
AbbVie bets $130M on UCB spinout, bagging early-phase Alzheimer's and depression prospect
Fierce Biotech
AbbVie
M&A
Neuroscience
Syndesi Therapeutics
UCB Pharma
Alzheimer's disease
depression
Flag link:
Watch out, AstraZeneca: UCB uncorks late-stage success for $2.1B Soliris rival
Watch out, AstraZeneca: UCB uncorks late-stage success for $2.1B Soliris rival
Endpoints
UCB Pharma
clinical trials
myasthenia gravis
AstraZeneca
Soliris
zilucoplan
Flag link:
Controversial opioid Zohydro ER pulled from the market
Controversial opioid Zohydro ER pulled from the market
Endpoints
UCB Pharma
epilepsy
Zogenix
Zohydro ER
Flag link:
UCB to buy Zogenix for nearly $2B in 'first step' for M&A in 2022
UCB to buy Zogenix for nearly $2B in 'first step' for M&A in 2022
BioPharma Dive
UCB Pharma
Zogenix
Fintepla
Dravet syndrome
Flag link:
UCB chases after Argenx with FcRN drug for myasthenia gravis
UCB chases after Argenx with FcRN drug for myasthenia gravis
Pharmaforum
UCB Pharma
anti-FcRn
myasthenia gravis
rozanolixizumab
Flag link:
UCB Signs Up To $1.5 Bln Deal With Novartis To Co-develop Two Parkinson's Disease Drugs
UCB Signs Up To $1.5 Bln Deal With Novartis To Co-develop Two Parkinson's Disease Drugs
NASDAQ
Novartis
UCB Pharma
drug development
Parkinson's Disease
Flag link:
UCB to restrict 340B discounts to hospitals using community pharmacies
UCB to restrict 340B discounts to hospitals using community pharmacies
Beckers Hospital Review
UCB Pharma
340B
hopsitals
drug discounts
Flag link:

Pages